6th International Chronic Graft-versus-Host Disease Symposium

    Change of congress venue. New congress venue is:
    Hotel Dubrovnik
    Ban Jelačić conference hall
    Ljudevita Gaja 1, 10000 Zagreb

    Hotel Dubrovnik is located right on the main square of Ban Jelacic in downtown Zagreb


    Hotel Dubrovnik
    Ban Jelačić conference hall
    Ljudevita Gaja 1, 10000 Zagreb

    ONLINE SUPORT6th International Chronic Graft-versus-Host Disease Symposium will be orgainized as hybrid symposium.
    ONLINE  suport will open an hour before the beginning of the sessions and close after the sessions.

    OFFICIAL LANGUAGESOfficial languages is English. Simultaneous translation will not be provided.

    CERTIFICATE OF ATTENDANCECertificates of attendance will be issued to all congress participants in accordance with the rules of professional chambers.


    Dear friends and colleagues,

    It is our great pleasure to invite you to the 6th International Chronic Graft-versus-Host Disease Symposium that will be organized in Zagreb, Croatia, from September 22nd – 23rd 2023. The symposium will be organized as a hybrid meeting.

    Chronic graft-versus-host disease (cGvHD) is still the most frequent late consequence after allogeneic hematopoietic stem cell transplantation (alloHSCT) which can last for many years causing severe medical, social and quality of life problems. However, more than ever before, the tools are at our hands to address cGvHD conclusively and improve outcomes of patients after alloHSCT. Such progress in a relatively rare and complex disease can be achieved only by the assertive interdisciplinary and multicenter international collaboration.

    This 6th International cGvHD Symposium in Zagreb again brings together prominent experts in the field of cGvHD from Europe, United States of America, Canada, South America, Australia, and other regions in the world. Symposium will be divided in several sections: 1) The new advances in biology and understanding of cGvHD, 2) Unmet needs in cGVHD, 3) cGvHD progress review (oral presentations of the best abstracts), 4) Interactive cases for Hematology Residents and young Hematologists, 5) What patients need vs physicians think – survivorship aspects, 6) Controversies in cGvHD treatment, 7) New drugs in development, 8) International aspects of cGvHD, and 9) Future of cGvHD.

    The goal of the meeting is to disseminate the most current knowledge regarding cGvHD, and to provide a venue for networking and establishing contacts for our future collaborations in addressing cGvHD. This event is expected to create a critical mass of investigators and colleagues who will carry this field in the near future. It is dedicated to physicians and scientists who are engaged in management, research, and advancing care of alloHSCT patients. With plans to continue an alternating North/America – European every other year schedule in 2024 (that year symposium will be organized in Vancouver, Canada) this venue is to become a leading international event for the cGvHD research and clinical practice.

    It is with delight that we invite you to attend and be part of this unique advanced continuing education experience.

    With warm regards,


    Dražen Pulanić (Zagreb, Croatia)

    Steven Z. Pavletic (Bethesda, MD, USA)

    Kirk R. Schultz (Vancouver, Canada)

    Radovan Vrhovac (Zagreb, Croatia)


    Croatian Cooperative Group for Hematological Diseases KROHEM


    Dražen Pulanić (Zagreb, Croatia)Steven Z. Pavletic (Bethesda, MD, USA)Kirk Schultz (Vancouver, Canada)Radovan Vrhovac (Zagreb, Croatia)




    1. The new advances in biology and understanding of cGvHD

    2. Unmet needs in cGVHD

    3. cGvHD progress review (oral presentations of the best abstracts)

    4. Interactive cases for Hematology Residents and young Hematologists

    5. What patients need vs physicians think – survivorship aspects

    6. Controversies in cGvHD treatment

    7. New drugs in development

    8. International aspects of cGvHD

    9. Future of cGvHD




    Meredith Cowden (USA)
    Cristobal Frutos (Paraguay)
    Juan Gea-Banacloche (USA)
    Hildegard Greinix (Austria)
    Nada Hamad (Australia)
    Andrew Harris (USA)
    Noa Holtzman (USA)
    Annie Im (USA)
    Stephanie Lee (USA)
    Kate Markey (USA)
    Christopher Melani (USA)
    David Michonneau (France)
    Steven Pavletic (USA)
    Olaf Penack (Germany)
    Iskra Pusic (USA)
    Helene Schoemans (Belgium)
    Kirk Schultz (Canada)
    Daniel Wolff (Germany)
    Robert Zeiser (Germany)


    PARTICIPANTS Early registration fee - until 31.Mar.2023. Late registration fee - from 1.April.2023.
    Onsite 6th International Chronic GvHD Symposium participant 250,00 EUR 350,00 EUR
    Online 6th International Chronic GvHD Symposium participant 200,00 EUR 250,00 EUR
    Students/young hematologists/fellows in training FREE FREE

    Advanced registration

     Online registration via registration form on the Congress web page


    On-site registration

     On-site registration will be possible during the Congress.


     Full registration fee includes

     • admission to all congress sessions and exhibition areas

    • congress materials (final Program, congress bag, certificate of attendance and points of professional chambers, conngress dinner, coffee brakes)


     Online registration fee includes

    • admission to all congress sessions by connecting to the online web platform of the Congress

    • pdf document with the booklet Final program

    • pdf document with Certificate of Attendance, and points of professional chambers



    All refund requests must be submitted in writing to the Congress agency Vivid Original (email: info@vivid-original.com) and must be received by May 15, 2023.Reimbursement of the fee less an administrative charge of 20 % and VAT will be refunded after the Congress. Cancellations received after May 15, 2023 will not be refunded.



    Herby we invite fellows/people in training who would like to present an oral presentation in the PART III: chronic GvHD Progress Review to submit an abstract for consideration by the Scientific Committee.

    There are 3 groups of topics:

    1) chronic GvHD – preclinical/basic research

    2) chronic GvHD – clinical research

    3) supportive care and quality of life.

    Total length of abstract must not exceed 500 words (included in this count: background, methods, results, and conclusions). The body of the abstract need to be structured as follows with the following subtitles: Background, Methods, Results, Conclusions. 1 Image/Graph and/or 1 Table is allowed (optional).

    The abstracts should be submitted in English. The Scientific Committee will determine whether the abstract will be accepted for an oral presentation. The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission to the Congress agency, and of all communications thereafter.

    July 1st – deadline for submitting abstract

    July 14th  –  decision regarding acceptance of abstract.

    Abstract Submission Form


    Technical organization information

    Applications for participation, payment of registration fees, information for sponsors, technical organization:

    Congress agency



    Korištenjem ove web stranice slažete se s našom politikom kolačića.